Management of brain metastases according to molecular subtypes
R Soffietti, M Ahluwalia, N Lin, R Rudà - Nature Reviews Neurology, 2020 - nature.com
The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …
Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities
LM Spring, E Nakajima, J Hutchinson, E Viscosi… - The …, 2021 - academic.oup.com
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab
govitecan (IMMU-132) is an antibody-drug conjugate that contains the irinotecan active …
govitecan (IMMU-132) is an antibody-drug conjugate that contains the irinotecan active …
Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer
DD Zhou, WQ Bai, XT Zhai, LP Sun, YS Zhen… - Military Medical …, 2021 - Springer
Background Triple-negative breast cancer (TNBC) is the most aggressive subtype and
occurs in approximately 15–20% of diagnosed breast cancers. TNBC is characterized by its …
occurs in approximately 15–20% of diagnosed breast cancers. TNBC is characterized by its …
Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth
M Zamberlan, A Boeckx, F Muller, F Vinelli, O Ek… - Journal of Experimental …, 2022 - Springer
Background Mitochondrial fusion and fission proteins have been nominated as druggable
targets in cancer. Whether their inhibition is efficacious in triple negative breast cancer …
targets in cancer. Whether their inhibition is efficacious in triple negative breast cancer …
Utilizing data visualization to identify survival and treatment differences between women with de novo and recurrent metastatic breast cancer
Introduction De novo stage IV metastatic breast cancer (MBC) and recurrent MBC are
considered the same when determining guideline-based care, but differences in treatment …
considered the same when determining guideline-based care, but differences in treatment …
Case Report of a Breast Mass with Three Types of Malignant Tumors—Squamous Cell Carcinoma, Invasive Ductal Carcinoma, and Breast Sarcoma
C Li, H Fang, H Lu - OncoTargets and therapy, 2021 - Taylor & Francis
Breast malignancy comprises malignant tumors originating from epithelial tissue and breast
sarcoma arising from mesodermal tissues. Despite heterogeneity in tumors, most malignant …
sarcoma arising from mesodermal tissues. Despite heterogeneity in tumors, most malignant …